SOURCE: Goldman Small Cap Research, Inc.

June 27, 2013 09:04 ET

Nuvilex Gains From Positive Cannabidiol Study

BALTIMORE, MD--(Marketwired - Jun 27, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a California Pacific Medical Center in San Francisco cannabidiol (CBD) study serves as an affirmation of the premise that CBD can aid in oncology treatment, and aids Nuvilex Inc.'s (OTCQB: NVLX) efforts in the space as the Company can leverage findings for use in protocol development for its own studies.

Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. is in the formative stages of studying the effect of CBD-based cancer treatments which may be combined with its highly efficacious live-cell encapsulation-based therapies used for oncology therapy. A number of companies have engaged in some form of lab testing or even animal testing of medical marijuana-based or CBD-based treatment for specific forms of cancer. With each succeeding study, the industry draws closer to the commencement of large-scale, meaningful oncology clinical trials and Nuvilex, along with cancer patients, arguably remain the greatest beneficiaries.

Leaders of the aforementioned CBD tests found that cannabidiol, a relatively non-toxic, non-psychoactive chemical compound found in the cannabis plant, could stop the metastasis or spread, of many kinds of aggressive cancer. Lab tests demonstrated that by using CBD to treat cancers with high levels of ID-1, a gene that causes cancer to spread, the CBD could essentially 'turn off' the ID-1 gene. As a result, the cancer cells stopped spreading and returned to a more "normal" state.

Considering that Nuvilex likely has much greater experience in successfully conducting oncology clinical trials than any other player in the space, it is anecdotal evidence such as the San Francisco study that may serve to shorten Nuvilex's own overall research and development times. Thus, Nuvilex's combination CBD-based cancer studies with live-cell encapsulation-based therapies might result in bringing a highly effective product potentially worth billions to market in a shorter period of time than its competitors. 

A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:

Contact Information